HLS Therapeutics (TSE:HLS) Stock Price Down 1.8% – Should You Sell?

HLS Therapeutics Inc. (TSE:HLS)’s share price dropped 1.8% during trading on Monday . The stock traded as low as C$3.89 and last traded at C$3.89. Approximately 32,710 shares changed hands during trading, an increase of 20% from the average daily volume of 27,313 shares. The stock had previously closed at C$3.96.

Analyst Upgrades and Downgrades

Separately, Raymond James upped their price target on shares of HLS Therapeutics from C$4.00 to C$5.00 in a research note on Friday, November 22nd.

HLS Therapeutics Trading Down 1.8 %

The company has a debt-to-equity ratio of 100.44, a quick ratio of 1.01 and a current ratio of 2.02. The business has a 50 day simple moving average of C$3.56 and a 200-day simple moving average of C$3.47. The stock has a market capitalization of C$123.66 million, a P/E ratio of -3.85 and a beta of 1.07.

About HLS Therapeutics

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.